Welcome to watch this video by Ioannis Parodis for Lupus Hub commenting on content from the 14th European Lupus Meeting in Bruges, Belgium.
Dr. Ioannis Parodis discusses the emergence of approved targeted therapies, such as belimumab, anifrolumab, and the recent approval of voclosporin for lupus nephritis at the 14th European Lupus Meeting. He underscores the importance of understanding the underlying mechanisms and clinical phenotypes of SLE, anticipating a shift towards molecular characterisation of the disease.
He also shares results from gene module analysis performed by our research group. In our study, lupus nephritis patients were categorised based on their interferon signature (low, intermediate, high) and analysed for their response to various therapies using systems biology. This approach highlights the potential for altering genetic signatures by targeting specific genes, paving the way for more effective, personalised therapies in the future.
